title: Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats.
abstract: Previous studies have shown that the loss of contractility in aortas from lipopolysaccharide (LPS)-treated rats is related to intracellular activation of matrix metalloproteinase (MMPs). However, the role of MMPs in the vascular refractoriness to vasoconstrictors has not been investigated in a model of polymicrobial sepsis. We evaluated the effects of the oral administration of the MMP inhibitors doxycycline or ONO-4817 in the in vitro vascular reactivity of aortic rings from rats subjected to the cecal ligation and puncture (CLP) model of sepsis. Both doxycycline and ONO-4817 did not change vascular responses in sham-operated rats, but fully prevented hyporeactivity to KCl, phenylephrine and angiotensin II in vessels from CLP rats. This protective effect was not associated with changes in hematological parameters or blood nitrate and nitrite. The refractoriness to contractile agents was accompanied by enhanced activity of MMP-2 in aorta from CLP rats, which was abrogated by MMP inhibitors. CLP-induced sepsis did not impair the levels of MMP-2 in aorta, but significantly reduced calponin-1, a regulatory protein of vascular contraction. In addition, augmented levels of TIMP-1 were found in vessels from CLP rats. All these differences were prevented by either doxycycline or ONO-4817. Our study shows, for the first time in the CLP rat model of sepsis, that the vascular refractoriness to different contractile agents induced by polymicrobial sepsis is associated with increased activity of MMP-2 and reduced amounts of calponin-1 in the aorta. These findings reinforce the importance of the enhanced activity of MMPs for vascular failure in septic shock.
authors: Department of Pharmacology, Universidade Federal do Paraná, Curitiba, PR, Brazil.
authors: Priscila
authors: P
authors: de Souza
authors: Departments of Pediatrics & Pharmacology, Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada.
authors: Richard
authors: R
authors: Schulz
authors: Laboratory of Cardiovascular Pharmacology, Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil. Electronic address: j.e.silva.santos@ufsc.br.
authors: José Eduardo
authors: JE
authors: da Silva-Santos
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002432:Cecum / Q000473:pathology / Q000601:surgery; D004195:Disease Models, Animal; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use*; D008026:Ligation; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010647:Phenyl Ethers / Q000008:administration & dosage / Q000627:therapeutic use*; D011677:Punctures; D017208:Rats, Wistar; D018805:Sepsis / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D014661:Vasoconstriction / Q000187:drug effects*
chemical_list: D061965:Matrix Metalloproteinase Inhibitors; C414368:N-hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide; D010647:Phenyl Ethers; D004318:Doxycycline
keywords: Calponin-1; Matrix metalloproteinase-2; Septic shock; Vasoplegia